Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H32N2O9 |
Molecular Weight | 528.551 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@H](N)[C@H](O)[C@H](C)O1)O[C@H]2C[C@](O)(CCO)CC3=C(O)C4=C(C(=N)C5=C(OC)C=CC=C5C4=O)C(O)=C23
InChI
InChIKey=GNCWGPLZJLZZPI-KUIJCEFOSA-N
InChI=1S/C27H32N2O9/c1-11-23(31)14(28)8-17(37-11)38-16-10-27(35,6-7-30)9-13-19(16)26(34)20-21(25(13)33)24(32)12-4-3-5-15(36-2)18(12)22(20)29/h3-5,11,14,16-17,23,29-31,33-35H,6-10,28H2,1-2H3/t11-,14-,16-,17-,23+,27-/m0/s1
Molecular Formula | C27H32N2O9 |
Molecular Weight | 528.551 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
GPX-150 is an anthracycline compound that is being tested for treatment in patients with soft-tissue sarcomas. This doxorubicin (DOX) analog does not show the cumulative dose-dependent cardiotoxicity of DOX. It works by reducing the formation of reactive oxygen species and the cardiotoxic metabolite, doxorubiciniol, the two pathways that are linked to the irreversible cardiotoxicity seen with DOX. Phase 1 clinical trials showed no irreversible, cumulative dose-dependent cardiotoxicity. A phase 2 study investigating the safety and efficacy of GPX-150 in patients with soft tissue sarcoma has been completed. No patients developed any evidence of irreversible, cumulative dose-dependent chronic cardiotoxicity. Toxicities reported include grade 3 anemia, neutropenia, and grade 4 leukopenia.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 03:21:16 GMT 2023
by
admin
on
Sat Dec 16 03:21:16 GMT 2023
|
Record UNII |
VI79RD8VNN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1594
Created by
admin on Sat Dec 16 03:21:16 GMT 2023 , Edited by admin on Sat Dec 16 03:21:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C78863
Created by
admin on Sat Dec 16 03:21:16 GMT 2023 , Edited by admin on Sat Dec 16 03:21:16 GMT 2023
|
PRIMARY | |||
|
135446069
Created by
admin on Sat Dec 16 03:21:16 GMT 2023 , Edited by admin on Sat Dec 16 03:21:16 GMT 2023
|
PRIMARY | |||
|
100000183564
Created by
admin on Sat Dec 16 03:21:16 GMT 2023 , Edited by admin on Sat Dec 16 03:21:16 GMT 2023
|
PRIMARY | |||
|
236095-26-4
Created by
admin on Sat Dec 16 03:21:16 GMT 2023 , Edited by admin on Sat Dec 16 03:21:16 GMT 2023
|
PRIMARY | |||
|
DB13103
Created by
admin on Sat Dec 16 03:21:16 GMT 2023 , Edited by admin on Sat Dec 16 03:21:16 GMT 2023
|
PRIMARY | |||
|
10847
Created by
admin on Sat Dec 16 03:21:16 GMT 2023 , Edited by admin on Sat Dec 16 03:21:16 GMT 2023
|
PRIMARY | |||
|
VI79RD8VNN
Created by
admin on Sat Dec 16 03:21:16 GMT 2023 , Edited by admin on Sat Dec 16 03:21:16 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |